标题
Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer
作者
关键词
Taxane, Pancreatic cancer, Drug resistance, Paclitaxel, Docetaxel, Nab-paclitaxel
出版物
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 78, Issue 6, Pages 1101-1111
出版商
Springer Nature
发表日期
2016-06-01
DOI
10.1007/s00280-016-3058-y
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- LBA19A MULTI-INSTITUTIONAL RANDOMIZED PHASE 2 TRIAL OF THE ONCOLYTIC VIRUS REOLYSIN IN THE FIRST LINE TREATMENT METASTATIC ADENOCARCINOMA OF THE PANCREAS (MAP)
- (2017) T. Bekaii-Saab et al. ANNALS OF ONCOLOGY
- A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study
- (2016) Steven J. Cohen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216
- (2016) B Mohelnikova-Duchonova et al. PHARMACOGENOMICS JOURNAL
- A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer
- (2015) G. Deplanque et al. ANNALS OF ONCOLOGY
- A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial†
- (2015) C. S. Fuchs et al. ANNALS OF ONCOLOGY
- BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts
- (2015) I Lohse et al. BRITISH JOURNAL OF CANCER
- Survivin expression and serum levels in pancreatic cancer
- (2015) He Dong et al. World Journal of Surgical Oncology
- βIII-Tubulin: A novel mediator of chemoresistance and metastases in pancreatic cancer
- (2015) Joshua A. McCarroll et al. Oncotarget
- Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
- (2014) T Golan et al. BRITISH JOURNAL OF CANCER
- Weekly Docetaxel as Salvage Therapy in Patients with Gemcitabine-Refractory Metastatic Pancreatic Cancer
- (2014) S. Cereda et al. JOURNAL OF CHEMOTHERAPY
- Role of solute carrier transporters in pancreatic cancer: a review
- (2014) Radmila Lemstrová et al. PHARMACOGENOMICS
- The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer
- (2013) Beatrice Mohelnikova-Duchonova et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Starring Role for Stellate Cells in the Pancreatic Cancer Microenvironment
- (2013) Minoti V. Apte et al. GASTROENTEROLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human equilibrative nucleoside transporter 1 (hENT1): Do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients?
- (2013) Beatrice Mohelnikova-Duchonova et al. PANCREATOLOGY
- A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer
- (2012) Peter J. Hosein et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer
- (2012) Andrew H. Ko et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials
- (2012) Wei-Xiang Qi et al. CURRENT MEDICAL RESEARCH AND OPINION
- nab -Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer
- (2012) Kristopher K. Frese et al. Cancer Discovery
- Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial
- (2011) J. M. Lohr et al. ANNALS OF ONCOLOGY
- Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study
- (2011) N. Xenidis et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis
- (2011) Hassan K. Dakik et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen)
- (2011) Michele Reni et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma
- (2011) Ana De Jesus-Acosta et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study
- (2011) Shimpei Maeda et al. International Journal of Clinical Oncology
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pancreatic Cancer: The Role of Pancreatic Stellate Cells in Tumor Progression
- (2011) Siri Dunér et al. PANCREATOLOGY
- Prognostic Relevance of Survivin in Pancreatic Endocrine Tumors
- (2011) Sara Ekeblad et al. WORLD JOURNAL OF SURGERY
- Weekly Paclitaxel After Failure of Gemcitabine in Pancreatic Cancer Patients with Malignant Ascites: A Retrospective Study
- (2010) T. Shukuya et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- CYP2A13, ADH1B, and ADH1C Gene Polymorphisms and Pancreatic Cancer Risk
- (2010) Beatrice Mohelnikova-Duchonova et al. PANCREAS
- Phase II Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients with Advanced Pancreatic Cancer
- (2009) Muhammad W. Saif et al. CANCER INVESTIGATION
- Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer
- (2008) Yoon Jae Kim et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacogenetic Pathway Analysis of Docetaxel Elimination
- (2008) SD Baker et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now